| 7/13/2009 | CVDD | Oscient Pharmaceuticals files bankruptcy, to sell antibiotic assets
|
| 5/15/2009 | CVDDSS | Oscient updates warning about lack of cash beyond the third quarter
|
| 5/1/2009 | CVDD | Oscient to issue $7.44 million 12.5% convertibles due 2011 in exchange for 5% convertibles
|
| 4/29/2009 | CVPP | Oscient holders swap some 5% convertibles due 2009 for 12.5% convertibles due 2011
|
| 3/26/2009 | CVDDSS | Oscient's cash may fail to support operations beyond third quarter
|
| 3/25/2009 | CVDDPPSS | Oscient Pharmaceuticals looks to raise capital, explores strategic options to prevent bankruptcy
|
| 11/24/2008 | CV | Oscient holders tender $213 million 3.5% convertibles in exchange offer
|
| 11/20/2008 | CV | Oscient Pharmaceuticals sets consideration to be issued in exchange offer for 3.5% convertibles
|
| 11/7/2008 | CV | Oscient Pharmaceuticals amends, extends exchange offer for 3.5% convertibles
|
| 10/21/2008 | CV | Oscient Pharmaceuticals starts exchange offer for 3.5% convertibles
|
| 9/11/2008 | CV | Market Commentary: Financial rout broadens, but Bank of America holds up; Oscient Pharma weakens after exchange news
|
| 9/10/2008 | CV | Oscient Pharmaceuticals plans exchange offer for 3.5% convertibles
|
| 4/26/2007 | CV | Oscient Pharmaceuticals gets tenders for 99% of 3.5% notes, 41% of 5% notes in exchange offer
|
| 4/25/2007 | CV | Market Commentary: Advanced Medical gains, RF Micro drops on earnings; Charming Shoppes up on debut; Oscient prices deal
|
| 4/25/2007 | CV | New Issue: Oscient sells upsized $60 million five-year 3.5% convertibles at 77.5, yields 10.7%, up 110.9%
|
| 4/18/2007 | CV | Oscient Pharmaceuticals increases new 3.5% convertibles offering
|
| 3/29/2007 | CV | Oscient Pharmaceuticals begins exchange offer for 3.5% convertibles, 5% promissory notes
|
| 3/15/2007 | CV | Oscient Pharmaceuticals plans exchange offer for 3.5% convertibles, 5% convertible promissory notes
|
| 2/23/2007 | CV | Reaping lessons from Wild Oats: Market value-based make-whole feature caps protection, says Lehman
|
| 9/26/2006 | BTCV | Oscient Pharmaceuticals files $100 million shelf registration
|
| 8/22/2006 | CV | Market Commentary: Mills higher on project financing deal; Developers REIT offer draws poor reviews; Scottish Re widens
|
| 4/10/2006 | CV | Market Commentary: Red Hat gains 8 points outright on acquisition; Oscient keeps sliding; Rentech deal sees poor interest
|
| 1/20/2006 | CV | Market Commentary: Hutchinson hovers around par; Schlumberger surges; Ford sags, Oscient tumbles
|
| 6/21/2004 | CV | Market Commentary: LabOne, Priceline deals emerge; Postbank sets €1 billion deal; Simon to distribute $900 million convert
|
| 6/8/2004 | CV | Market Commentary: Players taking a reality check in wake of Mandalay upset find the market discounted considerably
|
| 5/25/2004 | CV | Oscient greenshoe exercised, raising convertibles to $143.75 million
|
| 5/5/2004 | CV | New Issue: Oscient upsized $125 million convertible yields 3.5%, up 35%
|
| 5/5/2004 | CV | Market Commentary: Oscient Pharmaceuticals hits par 1/8 bid on first day of trading
|
| 5/4/2004 | CV | Market Commentary: ImClone trades off gray levels; five new deals surface after Fed leaves rates alone
|
| 5/3/2004 | CV | Market Commentary: ImClone bid at 102.75 even after terms tightened; Oscient emerges; Albertson's at bat; Conseco Thursday
|
| 5/3/2004 | CV | Oscient Pharma $75 million convertible talked at 3.5%-4.0%, up 30%-35%
|
